- Home
- CTW vs CRBP Comparison
CTW vs CRBP Comparison
Compare CTW & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTW | CRBP |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.2M | 184.4M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | CTW | CRBP |
|---|---|---|
| Price | $2.33 | $9.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | 22.4K | ★ 317.6K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | $22.41 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $1.10 | $7.12 |
| 52 Week High | $3.14 | $20.56 |
Technical Indicators
Market Signals| Indicator | CTW | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 45.02 | 54.72 |
| Support Level | $1.98 | $7.86 |
| Resistance Level | $2.51 | $9.73 |
| Average True Range (ATR) | 0.23 | 0.44 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 34.72 | 56.52 |
Price Performance
Historical ComparisonAbout CTW CTW Cayman Class A Ordinary Shares
CTW operates as a gaming platform company providing instant access to free-to-play, browser-based games inspired by popular Japanese animation, including "So I'm a Spider, So What? Ruler of the Labyrinth, Arifureta: From Commonplace to World's Strongest - Rebellion Soul", and "Queen's Blade Limit Break". CTW delivers these games through its flagship HTML5 platform, G123.jp.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.